The aim of this randomized controlled trial (RCT) is to compare the incidence of paclitaxel-induced grade 2 or higher sensory peripheral neuropathy, evaluated using the CTCAE version 5.0, between patients receiving surgical glove-compression therapy (SGCT) and those in the control group.
The main question is whether SGCT is effective in preventing paclitaxel-induced sensory peripheral neuropathy.
* Intervention group: receive SGCT. * Control group: receive non-compressive plastic gloves.
Signed Informed Consent Form
Age 18 years or older at the time of signing Informed Consent Form
Patients with any pathological diagnosis of solid tumor, such as breast cancer or lung cancer
Patients scheduled to be receiving intravenous paclitaxel or paclitaxel-based regimen every 3 weeks
Patients whose received chemotherapeutic agents that could cause neuropathy, e.g. taxane-based or platinum-based chemotherapy and anti-microtubule
History of neuropathy
History of carpal tunnel syndrome
History of allergic reactions to latex or gloves